Author:
Namura Kazuhiro,Minamimoto Ryogo,Yao Masahiro,Makiyama Kazuhide,Murakami Takayuki,Sano Futoshi,Hayashi Narihiko,Tateishi Ukihide,Ishigaki Hanako,Kishida Takeshi,Miura Takeshi,Kobayashi Kazuki,Noguchi Sumio,Inoue Tomio,Kubota Yoshinobu,Nakaigawa Noboru
Abstract
Abstract
Background
In this era of molecular targeting therapy when various systematic treatments can be selected, prognostic biomarkers are required for the purpose of risk-directed therapy selection. Numerous reports of various malignancies have revealed that 18-Fluoro-2-deoxy-D-glucose (18F-FDG) accumulation, as evaluated by positron emission tomography, can be used to predict the prognosis of patients. The purpose of this study was to evaluate the impact of the maximum standardized uptake value (SUVmax) from 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) on survival for patients with advanced renal cell carcinoma (RCC).
Methods
A total of 26 patients with advanced or metastatic RCC were enrolled in this study. The FDG uptake of all RCC lesions diagnosed by conventional CT was evaluated by 18F-FDG PET/CT. The impact of SUVmax on patient survival was analyzed prospectively.
Results
FDG uptake was detected in 230 of 243 lesions (94.7%) excluding lung or liver metastases with diameters of less than 1 cm. The SUVmax of 26 patients ranged between 1.4 and 16.6 (mean 8.8 ± 4.0). The patients with RCC tumors showing high SUVmax demonstrated poor prognosis (P = 0.005 hazard ratio 1.326, 95% CI 1.089-1.614). The survival between patients with SUVmax equal to the mean of SUVmax, 8.8 or more and patients with SUVmax less than 8.8 were statistically different (P = 0.0012). This is the first report to evaluate the impact of SUVmax on advanced RCC patient survival. However, the number of patients and the follow-up period were still not extensive enough to settle this important question conclusively.
Conclusions
The survival of patients with advanced RCC can be predicted by evaluating their SUVmax using 18F-FDG-PET/CT. 18F-FDG-PET/CT has potency as an "imaging biomarker" to provide helpful information for the clinical decision-making.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference26 articles.
1. Chow WH, Devesa SS, Warren JL, Fraumeni JF: Rising incidence of renal cell carcinoma in the United States. JAMA. 1999, 281: 1628-31. 10.1001/jama.281.17.1628.
2. Linehan WM, Walther MM, Alexander RB, Rosenberg SA: Adoptive immunotherapy of renal cell carcinoma.:studies from the Surgery Branch, National Cancer Institute. Semin Urol. 1993, 11: 41-3.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol ClinNorth Am. 2003, 30: 843-852. 10.1016/S0094-0143(03)00056-9.
4. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med. 1996, 335: 865-75. 10.1056/NEJM199609193351207.
5. Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y: Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. Eur Urol. 2009, 57: 317-26. 10.1016/j.eururo.2008.12.026.
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献